文献速递肾移植

肾移植受者BK多瘤病毒相关肾病的发病率、危险因素与结局

Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients With BK Polyomavirus-Associated Nephropathy.
PubMed 文献 · Kidney Int Rep · 2022-12-30

BKPyVAN组移植物丢失、排斥和死亡更常见,且与全因和死亡删失移植物丢失风险增加相关,但与死亡率无关。

要点

  • BKPyVAN发生于3%的肾移植受者,中位移植后4.8个月。
  • BKPyVAN组移植物丢失35% vs 21%,排斥42% vs 25%,死亡18% vs 13%。
  • BKPyVAN与全因和死亡删失移植物丢失风险增加相关,但与死亡率无关。

核心结论

  • BKPyVAN与全因和死亡删失移植物丢失风险增加相关,但与死亡率无关。
  • 迫切需要干预性试验评估减少免疫抑制和新型策略的疗效,以尽量减少BKPyVAN相关的不良结局。

主要发现

  • BKPyVAN发生于460例受者(3%),中位移植后时间为4.8个月(四分位距3.1-10.8)。
  • BKPyVAN组移植物丢失35% vs 21%(P < 0.001),排斥42% vs 25%(P < 0.001),死亡18% vs 13%(P = 0.002)。
  • BKPyVAN后免疫抑制最常见调整为他克莫司剂量减少≤50%(172例,51%)和霉酚酸酯剂量减少≤50%(134例,40%),其次为霉酚酸酯转换为来氟米特(62例,19%)和他克莫司转换为环孢素(20例,6%)。
  • 与BKPyVAN发生相关的因素包括男性(调整HR 1.66;95%CI 1.34-2.05)、受者年龄≥70 vs <20(2.46;1.30-4.65)、受者血型A vs B(2.00;1.19-3.34)、供者年龄≥70 vs <20(2.99;1.71-5.22)、较早年代(1.74;1.35-2.25)、供受者种族不匹配(1.52;1.23-1.87)、使用他克莫司(1.46;1.11-1.91)以及在低容量移植中心移植(1.61;1.24-2.09)。
  • BKPyVAN发生与全因移植物丢失风险增加(1.75;1.46-2.09)和死亡删失移植物丢失风险增加(2.49;1.99-3.11)相关,但与死亡率无关(1.15;0.91-1.45)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: BK polyomavirus-associated nephropathy (BKPyVAN) is associated with graft dysfunction and loss; however, knowledge of immunosuppression reduction strategies and long-term graft, and patient outcomes across the disease spectrum is lacking. METHODS: This cohort study included 14,697 kidney transplant recipients in Australia and New Zealand (2005-2019), followed for 91,306 person years. RESULTS: BKPyVAN occurred in 460 recipients (3%) at a median posttransplant time of 4.8 months (interquartile range, 3.1-10.8). Graft loss (35% vs. 21%, P < 0.001), rejection (42% vs. 25%, P < 0.001), and death (18% vs. 13%, P = 0.002) were more common in the BKPyVAN group. The most frequent changes in immunosuppression after BKPyVAN were reduction (≤50%) in tacrolimus (172, 51%) and mycophenolate doses (134, 40%), followed by the conversion of mycophenolate to leflunomide (62, 19%) and tacrolimus to ciclosporin (20, 6%). Factors associated with the development of BKPyVAN included (adjusted hazard ratio [HR]; 95% confidence interval) male sex (1.66; 1.34-2.05), recipient age (≥70 vs. <20 [2.46; 1.30-4.65]), recipient blood group (A vs. B [2.00; 1.19-3.34]), donor age (≥70 vs. <20 [2.99; 1.71-5.22]), earlier era (1.74; 1.35-2.25), donor/recipient ethnic mismatch (1.52; 1.23-1.87), tacrolimus use (1.46; 1.11-1.91), and transplantation at a lower-volume transplant center (1.61; 1.24-2.09). The development of BKPyVAN was associated with an increased risk of all-cause (1.75; 1.46-2.09) and death-censored graft loss (2.49; 1.99-3.11), but not mortality (1.15; 0.91-1.45). CONCLUSIONS: BKPyVAN is associated with an increased risk of all-cause and death-censored graft loss, but not death. Interventional trials are urgently needed to evaluate the efficacy of immunosuppression reduction and novel strategies to minimize the adverse outcomes associated with BKPyVAN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gately R, Milanzi E, Lim W, et al. Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients With BK Polyomavirus-Associated Nephropathy. Kidney Int Rep. 2022. PMID: 36938086. doi:10.1016/j.ekir.2022.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。